Aligos co-founders shoot back at J&J IP complaint with one of their own alleging fraud
This story goes all the way back to 2014.
In November of 2014, Johnson & Johnson acquired Alios BioPharma, an infectious disease biotech that was co-founded by Lawrence Blatt and Leonid Beigelman.
Following J&J’s 2014 acquisition, Blatt and Beigelman would become employees at J&J’s Janssen arm, with Blatt being the global head of infectious diseases and vaccines and Beigelman being Janssen’s VP of medicinal chemistry. But Blatt and Beigelman left Janssen in 2017, starting Aligos one year later.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.